Welcome!
Coastal Cancer Center provides patients with cancer and blood disorders the most current advances in treatment close to the support and convenience of home. Doctors and clinical staff understand that cancer care is about more than medical treatment – it is about care for the whole person. Patients are treated through a team approach in a relaxed, community-based environment of care, compassion and hope.
 Click here to learn more about our QOPI Certification |
 |
Latest Cancer News
Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug
(05-22-2013)
Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by... Continue Reading
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors (05-22-2013)
Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin LEXINGTON, Mass., May 22,... Continue Reading
Biomarker Analysis Identifies Women Most Likely to Benefit From Kadcyla (05-20-2013)
Among women with metastatic, HER2-positive breast cancer, those with the highest tumor HER2 levels benefit the most from the drug Kadcyla™ (ado-trastuzumab emtansine, formerly known as T-DM1), according... Continue Reading
Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by... Continue Reading
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors (05-22-2013)
Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin LEXINGTON, Mass., May 22,... Continue Reading
Biomarker Analysis Identifies Women Most Likely to Benefit From Kadcyla (05-20-2013)
Among women with metastatic, HER2-positive breast cancer, those with the highest tumor HER2 levels benefit the most from the drug Kadcyla™ (ado-trastuzumab emtansine, formerly known as T-DM1), according... Continue Reading
